Financials Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:57:21 10/09/2024 BST			5-day change	1st Jan Change
16.14 ^USD	-1.07%		-3.14%	-15.97%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

Projected Income Statement: Arcus Biosciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	15	77.52	382.9	112	117	271.2	192.6	286.2
Change	-	416.78%	393.93%	-70.75%	4.46%	131.78%	-28.98%	48.6%
EBITDA ¹	-85.13	-121.1	58.09	-274	-332	-284.2	-377.1	-432.1
Change	-	42.23%	-	-	21.17%	14.38%	-32.66%	-14.6%
EBIT ¹	-88.71	-124.2	54.25	-280	-340	-308.6	-451.3	-388.3
Change	-	40.05%	-	-	21.43%	9.23%	-46.24%	13.98%
Interest Paid	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-84.71	-122.9	54.64	-266	-301	-303.7	-507.7	-386.8
Change	-	45.03%	-	-	13.16%	-0.89%	-67.18%	23.81%
Net income ¹	-84.71	-122.9	52.83	-267	-307	-281	-446.5	-357.9
Change	-	45.03%	-	-	14.98%	8.48%	-58.92%	19.84%
Announcement Date	05/03/20	24/02/21	23/02/22	28/02/23	21/02/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	1.75	9.75	1.75	1.75	64.53	9.487	9.461	9.461	9.461	354.5	18	26.76	33.58	34	25	29	32	31	145	39	61.65	28.21	29.27	29.27	29.27	29.27
Change	-	457.14%	-82.05%	0%	3,587.43%	-85.3%	-0.27%	0%	0%	3,646.95%	-94.92%	48.62%	25.49%	1.25%	-26.47%	16%	10.34%	-3.12%	367.74%	-73.1%	58.08%	-54.25%	3.76%	0%	0%	0%
EBITDA ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-72.52	-	-	-	-88	7	-104	-50.88	-115.3	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-100%	-	-	-	-	-	51.08%	-126.52%	100%	-	-	-
EBIT ¹	-23.25	-17.53	-28.4	-45.38	1.552	-52.01	-72.75	-76.14	-78.14	281.3	-67.18	-68.98	-69.4	-74	-86	-83	-80	-91	-16	-106	-80.42	-122	-120	-122	-125	-129
Change	-	-24.61%	62.04%	59.77%	-	-	39.87%	4.66%	2.63%	-	-	2.68%	0.6%	6.63%	16.22%	-3.49%	-3.61%	13.75%	-82.42%	562.5%	24.13%	-51.67%	1.62%	-1.67%	-2.46%	-3.2%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-22.35	-16.6	-27.75	-45.07	1.822	-51.85	-72.59	-75.97	-77.98	281.2	-66.99	-66.63	-64.92	-67	-78	-74	-69	-80	-4	-93	-90.25	-121.8	-120	-122	-125	-129
Change	-	-25.74%	67.21%	62.41%	-	-	40%	4.65%	2.64%	-	-	-0.53%	-2.57%	3.21%	16.42%	-5.13%	-6.76%	15.94%	-95%	2,225%	2.95%	-34.94%	1.47%	-1.67%	-2.46%	-3.2%
Net income ¹	-22.35	-16.6	-27.75	-45.07	1.822	-51.85	-72.59	-75.97	-77.98	279.4	-67.99	-66.63	-64.92	-67	-80	-75	-69	-81	-4	-93	-68.56	-115.3	-120	-122	-125	-129
Change	-	-25.74%	67.21%	62.41%	-	-	40%	4.65%	2.64%	-	-	-2%	-2.57%	3.21%	19.4%	-6.25%	-8%	17.39%	-95.06%	2,225%	26.28%	-68.17%	-4.08%	-1.67%	-2.46%	-3.2%
Announcement Date	05/11/19	05/03/20	05/05/20	06/08/20	05/11/20	24/02/21	05/05/21	05/08/21	08/11/21	23/02/22	09/05/22	03/08/22	02/11/22	28/02/23	09/05/23	07/08/23	07/11/23	21/02/24	08/05/24	08/08/24	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Arcus Biosciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-57.9	-729	-499	-1,009	-759	-860	-593	-653
Change	-	-1,359.07%	-168.45%	-302.2%	-175.22%	-213.31%	-168.95%	-210.12%
Announcement Date	05/03/20	24/02/21	23/02/22	28/02/23	21/02/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Arcus Biosciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2024	2025	2026
CAPEX ¹	1.925	3.055	26.08	6	16	19.5	21.5
Change	-	58.7%	753.62%	-76.99%	-	21.88%	10.26%
Free Cash Flow (FCF) ¹	-75.39	108.1	-282.2	432	-175	-446.5	-142
Change	-	-243.41%	-361.06%	-253.06%	-	155.14%	-68.2%
Announcement Date	05/03/20	24/02/21	23/02/22	28/02/23	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Arcus Biosciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-567.54%	-156.21%	15.17%	-244.64%	-283.76%	-104.81%	-195.79%	-151%
EBIT Margin (%)	-591.39%	-160.27%	14.17%	-250%	-290.6%	-113.8%	-234.35%	-135.67%
EBT Margin (%)	-564.73%	-158.49%	14.27%	-237.5%	-257.26%	-111.98%	-263.61%	-135.16%
Net margin (%)	-564.73%	-158.49%	13.8%	-238.39%	-262.39%	-103.61%	-231.85%	-125.08%
FCF margin (%)	-502.58%	139.47%	-73.72%	385.71%	-	-64.53%	-231.84%	-49.62%
FCF / Net Income (%)	88.99%	-88%	-534.26%	-161.8%	-	62.28%	99.99%	39.67%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-	-	7.86%	-35.62%	-54.87%	-57.13%	-107.77%	-80.17%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	12.83%	3.94%	6.81%	5.36%	-	5.9%	10.13%	7.51%
CAPEX / EBITDA (%)	-2.26%	-2.52%	44.89%	-2.19%	-	-5.63%	-5.17%	-4.98%
CAPEX / FCF (%)	-2.55%	2.83%	-9.24%	1.39%	-	-9.14%	-4.37%	-15.14%
Items per share
Cash flow per share ¹	-	-	-	6.083	-4.135	1.405	-3.865	-
Change	-	-	-	-	-167.97%	-133.98%	-375.06%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	9.012	6.119	5	0.71	-2.71
Change	-	-	-	-	-32.1%	-18.29%	-85.8%	-481.69%
EPS ¹	-1.93	-2.24	0.71	-3.71	-4.15	-3.053	-4.805	-3.564
Change	-	16.06%	-131.7%	-622.54%	11.86%	-26.43%	57.37%	-25.83%
Nbr of stocks (in thousands)	45,859	64,923	70,249	72,408	74,856	91,428	91,428	91,428
Announcement Date	05/03/20	24/02/21	23/02/22	28/02/23	21/02/24	-	-	-